Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Great Article!

<< Previous

Bullboard Posts

Next >>

Post by Yellowknifer69on Apr 22, 2021 2:27pm

143 Views

Post# 33046303

Re: Great Article!

Hey Longs:

Someone shared this link on another board. If anything it gives food for thought to our investing strategies!

https://www.griproom.com/fun/why-your-stock-is-always-red?fbclid=IwAR3Sf27S2jKwLKonf4bHfM0L9zLqMlu3RVPn4BKDmw6RD3lHFSXKLCuP19Q

Stay Long Boys,

Yellowknifer

<< Previous

Bullboard Posts

Next >>

How a junior advances one of the largest undeveloped diamond projects